Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same author

The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

Intensive care medicine·2026
Same author

Editorial: Immunological aspects and immunotherapy in gynecologic cancers.

Frontiers in immunology·2026
Same author

Real-world data on the clinical impact of molecular tumor boards in high- and low-grade serous ovarian cancer.

Frontiers in oncology·2026
Same author

TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

Leukemia·2026
Same author

Dual inhibition of PP2A and WEE1 induces apoptosis and mitotic catastrophe in cancer cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

相关实验视频

Updated: Jun 15, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

254

针对性CD47检查点封锁使用 mesothelin 定向抗体构造,用于增强固体瘤特异性免疫治疗.

Anna Reischer1,2, Alexandra Leutbecher1,2, Björn Hiller3

  • 1Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.

Cancer immunology, immunotherapy : CII
|May 22, 2025
PubMed
概括

这项研究开发了一种新型抗体结构,以阻止癌症中的CD47免疫检查点. 这种新疗法专门针对瘤,减少了其他CD47抑制剂所见的有毒副作用.

关键词:
在CD47SIRPα中.天生的免疫检查点.梅索他林是其中一种.多功能抗体 多功能抗体固体瘤是一种固体瘤.

更多相关视频

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.9K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

6.8K

相关实验视频

Last Updated: Jun 15, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

254
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.9K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

6.8K

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 生物技术是生物技术.

背景情况:

  • CD47是一个关键的免疫检查点,在许多癌症中被上调,通过SIRPα传递"不要吃我"信号来实现免疫逃避.
  • 阻断CD47-SIRPα轴是一种有前途的癌症免疫疗法,但面临着诸如针对性非白血病毒性和抗原沉降效应等挑战.

研究的目的:

  • 开发一种多功能抗体结构,将低亲和度CD47阻断与瘤特异向相结合,以减轻CD47相关的毒性.
  • 在临床前癌症模型中评估新型抗体SIRPα-αMSLN LicMAb的疗效和安全性.

主要方法:

  • 通过将SIRPα域与抗美索林 (MSLN) 抗体融合,创建了一个局部抑制检查点单克隆抗体 (LicMAb).
  • 在上皮卵巢癌 (EOC) 和胰腺管腺癌 (PDAC) 模型中评估了瘤特异性结合,CD47阻断和免疫反应 (ADCC,ADCP).

主要成果:

  • SIRPα-αMSLN LicMAb表现出瘤特异性结合和CD47阻断,即使存在健康细胞.
  • LicMAb诱导了NK细胞介导的细胞毒性,并增强了EOC和PDAC细胞的细胞化.
  • 在EOC有机体中观察到特定驱动的细胞死亡,证实了瘤受限活性.

结论:

  • SIRPα-αMSLN LicMAb有效地以瘤受限的方式阻止CD47-SIRPα轴.
  • 这种方法表明,通过将特定的抗瘤反应与减少瘤外毒性相结合,有可能治疗固体瘤.